Jeremy Jones

Dr. Jeremy Jones

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2014 in Journal of Molecular Endocrinology
Verified
Journal Article
Closed access
PDF file
YZYe Zhou
Ye Zhou
EBEric C Bolton
Eric C Bolton
JJJeremy Jones
Jeremy Jones
Androgens and androgen receptor (AR) signaling are necessary for prostate development and homeostasis. AR signaling also drives the growth of nearly all prostate cancer cells. The role of androgens and AR signaling has been well characterized in metastatic prostate cancer, where it has been shown that prostate cancer cells are exquisitely adept at maintaining functional AR signaling to drive cancer growth. As androgens and AR signaling are so intimately involved in prostate development and the proliferation of advanced prostate cancer, it stands to reason that androgens and AR are also involved in prostate cancer initiation and the early stages of cancer growth, yet little is known of this process. In this review, we summarize the current state of knowledge concerning the role of androgens and AR signaling in prostate tissue, from development to metastatic, castration-resistant prostate cancer, and use that information to suggest potential roles for androgens and AR in prostate cancer initiation.

19 December 2017 in Cancer
Verified
Journal Article
Closed access
PDF file
SPSumanta Kumar Pal
Sumanta Kumar Pal
JPJaymala Patel
Jaymala Patel
MHMiaoling He
Miaoling He
BFBrad Foulk
Brad Foulk
KKKatherine Kraft
Katherine Kraft
JJJeremy Jones
Jeremy Jones

Verified
Journal Article
Open access
PDF file
SPSumanta K Pal
Sumanta K Pal
DMDayson Moreria
Dayson Moreria
HWHaejung Won
Haejung Won
SWSeok Voon White
Seok Voon White
PDPryanka Duttagupta
Pryanka Duttagupta
MKMarcin Kortylewski
Marcin Kortylewski
Currently, there are two Food and Drug Administration (FDA)-approved drugs for androgen deprivation therapy (ADT) of metastatic castration-resistant prostate cancer (mCRPC) patients: abiraterone and enzalutamide. However, our understanding of the effect of these therapies on the immune system in mCRPC patients remains limited. Here, we examined how abiraterone and enzalutamide treatment affects levels of soluble immune mediators in plasma and in circulating immune cells of 44 mCRPC patients. We found that the baseline levels of cytokines fibroblast growth factor (FGF), granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin 10 (IL-10), and IL-6 were significantly lower in ADT-sensitive compared to de novo resistant patients. In addition, resistant patients showed significantly lower T cell frequencies. When comparing the levels of cytokines over the course of treatment, we observed that the levels of proinflammatory mediators, such as interferon-γ (IFN-γ), IL-5, macrophage inflammatory protein 1 alpha (MIP-1α), and tumor necrosis factor alpha (TNFα), were significantly increased in the ADT-sensitive patients. At the same time, the abiraterone/enzalutamide therapy did not reduce the percentage of tolerogenic myeloid cell populations, such as polymorphonuclear myeloid-derived suppressor cells, which retained unaltered expression of programmed death-ligand 1 (PD-L1) and B7-H3. Overall, our results suggest that certain immune markers, such as IL-6 and the frequency of effector T cells, could be predictive of therapeutic response to ADT therapies in mCRPC patients.

1 April 2015 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
SPSumanta K. Pal
Sumanta K. Pal
MHMiaoling He
Miaoling He
TWTimothy Wilson
Timothy Wilson
XLXueli Liu
Xueli Liu
KZKeqiang Zhang
Keqiang Zhang
JJJeremy Jones
Jeremy Jones

3 January 2014 in ACS Chemical Biology
Verified
Journal Article
Closed access
MLMinyoung Lim
Minyoung Lim
MOMaya Otto-Duessel
Maya Otto-Duessel
MHMiaoling He
Miaoling He
LSLeila Su
Leila Su
DNDan Nguyen
Dan Nguyen
JJJeremy Jones
Jeremy Jones

15 January 2015 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
SPSumanta K. Pal
Sumanta K. Pal
MHMiaoling He
Miaoling He
TTTommy Tong
Tommy Tong
HWHuiqing Wu
Huiqing Wu
XLXueli Liu
Xueli Liu
JJJeremy Jones
Jeremy Jones
Sarcomatoid metastatic renal cell carcinoma (mRCC) is associated with a poor prognosis, and the biology of the disease has been inadequately characterized. RNA sequencing (RNA-seq) was performed on adjacent benign, clear cell, and sarcomatoid components from clinical specimens with sarcomatoid mRCC. M phase and cell-cycle pathways were enriched in sarcomatoid versus adjacent clear cell components, suggesting greater cell proliferation. The expression of aurora kinase A (AURKA) was increased as part of these pathways, and its increased expression was validated by quantitative PCR (qPCR). Immunohistochemical (IHC) analysis revealed that AURKA levels were increased in sarcomatoid tissue compared with their benign or clear cell parts. The increase in AURKA correlated with increased mTOR pathway activity, as evidenced by increased expression of phosphorylated mTOR (S2448) and ribosomal protein S6K (T389). When AURKA was stably expressed in a RCC cell line (Renca), it resulted in increased expression and activity of mTOR, suggesting that overexpression of AURKA can activate the mTOR pathway. These results warrant the analysis of a larger clinical cohort and suggest that targeting AURKA and/or mTOR in patients with sarcomatoid mRCC should be explored. Implications: Comparative RNA-seq of adjacent sarcomatoid and clear cell histology of RCC indicates a proliferative phenotype and increased AURKA-dependent activation of mTOR signaling in sarcomatoid RCC, which could be targeted by available agents. Mol Cancer Res; 13(1); 130–7. ©2014 AACR.